• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Yield10 Bioscience Announces 1-for-24 Reverse Stock Split

    5/1/24 8:30:00 AM ET
    $YTEN
    Get the next $YTEN alert in real time by email

    WOBURN, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that it will effect a 1-for-24 reverse stock split of its common stock, following stockholder approval of the reverse stock split at its special stockholder meeting held on April 26, 2024. The 1-for-24 reverse stock split will be effective as of 5:00 p.m. Eastern Time, after the close of trading on the Nasdaq Capital Market, on Thursday, May 2, 2024, and the Company's common stock will begin trading on a split-adjusted basis on Friday, May 3, 2024.  

    The reverse stock split will reduce the number of shares of the Company's common stock currently outstanding from 15,420,951 shares to 642,539 shares.

    Proportional adjustments will be made to the Company's outstanding stock options, warrants and restricted stock units and to the number of shares issued and issuable under the Company's equity compensation plans. The number of authorized shares of the Company's common stock will remain 60 million shares.

    The reverse stock split is intended to increase the market price per share of the Company's common stock to allow the Company to maintain the listing of its common stock on The Nasdaq Capital Market. The Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "YTEN." The new CUSIP number for the common stock following the reverse stock split will be 98585K854.

    Information for Stockholders

    Upon the effectiveness of the reverse stock split, each 24 shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.01 per share. The reverse stock split will not modify the rights or preferences of the common stock. No fractional shares of common stock will be issued as a result of the reverse split. Instead, stockholders who otherwise would be entitled to receive fractional shares will be entitled to receive cash in an amount equal to the product obtained by multiplying (i) the closing price of Yield10 common stock on May 2, 2024, as adjusted for the reverse stock split, by (ii) the number of shares of common stock held by the stockholder that would otherwise have been exchanged for such fractional share interest.

    The Company's transfer agent, Equiniti Trust Company, LLC, will act as its exchange agent for the reverse stock split. Registered stockholders holding pre-split shares of the Company's common stock are not required to take any action to receive post-split shares. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers' particular processes, and will not be required to take any action in connection with the reverse stock split. Equiniti Trust Company, LLC can be reached at (800) 937-5449.

    Additional information about the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 4, 2024, a copy of which is available at www.sec.gov or at www.yield10bio.com under the SEC Filings tab located on the Investors page of the Company's website at www.yield10bio.com.

    About Yield10 Bioscience

    Yield10 Bioscience, Inc. is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa ("Camelina") as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and, in the future, PHA biomaterials for use as biodegradable bioplastics. Subject to the availability of sufficient financial resources to continue operations, our commercial plan is based on establishing a grain contracting business leveraging our proprietary elite Camelina seed varieties, focusing on the production of omega-3 oils for nutritional applications and partnering or licensing our advanced Camelina gene technologies to biofuel value chain partners to support their goals of meeting the growing demand for low-carbon intensity feedstock oil. Yield10 is headquartered in Woburn, MA and has a Canadian subsidiary, Yield10 Oilseeds Inc., located in Saskatoon, Canada.

    For more information about the Company, please visit www.yield10bio.com, or follow the Company on X (formerly Twitter), Facebook and LinkedIn.

    (YTEN-G)

    Safe Harbor for Forward-Looking Statements  

    This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, statements regarding the Company's expectations for the impact of the reverse stock split on the market price of the Company's stock and the Company's ability to regain and maintain compliance with Nasdaq listing requirements, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, the Company's ability to secure adequate funding in the near term to continue operations and to remain listed on the Nasdaq Stock Market, as to which no assurance can be given, as well as the risks and uncertainties detailed in Yield10's filings with the Securities and Exchange Commission. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.

    Contacts:

    Yield10 Bioscience:

    Lynne H. Brum, (617) 682-4693, [email protected]

     



    Primary Logo

    Get the next $YTEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $YTEN

    DatePrice TargetRatingAnalyst
    2/8/2024Buy → Hold
    Lake Street
    3/10/2022$18.00 → $9.00Buy
    Maxim Group
    More analyst ratings

    $YTEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP Research and CSO Snell Kristi covered exercise/tax liability with 877 shares, decreasing direct ownership by 11% to 6,999 units (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      8/20/24 3:15:23 PM ET
      $YTEN
    • VP Planning and Communications Brum Lynne H covered exercise/tax liability with 731 shares, decreasing direct ownership by 11% to 5,867 units (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      8/19/24 8:11:23 PM ET
      $YTEN
    • VP Finance and CAO Haaser Charles B covered exercise/tax liability with 731 shares, decreasing direct ownership by 11% to 5,949 units (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      8/19/24 8:10:36 PM ET
      $YTEN

    $YTEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Schuler Jack W bought $497,250 worth of shares (765,000 units at $0.65) (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      10/10/23 4:41:49 PM ET
      $YTEN

    $YTEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals

      Special Meeting Adjourned to Thursday, November 21, 2024 WOBURN, MA / ACCESSWIRE / November 8, 2024 / Yield10 Bioscience, Inc. (OTCQB:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that its Special Meeting of Stockholders (the "Special Meeting"), scheduled to be held at 11:00 a.m., Eastern Time, on November 8, 2024, was convened and adjourned, without any business being conducted, due to lack of sufficient votes in favor of the key proposals related to the Asset Sale to Nuseed and the Dissolution proposal.To pass the proposals, more than 50% of the shares of common stock outstanding and entitled to vote as of the close of business on October 3, 2024

      11/8/24 11:20:00 AM ET
      $YTEN
    • Yield10 Bioscience Announces Second Quarter 2024 Financial Results

      WOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the second quarter ended June 30, 2024. "We continue to work closely with the Nufarm team to finalize the asset purchase agreement announced in July," said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10. "We believe that the transition of our Omega-3 Camelina program to Nufarm is in the best interest of our shareholders, business partners, and employees. Receipt of the initial $3 million payment and progress toward earning an additional $2 million milestone payment is enabling

      8/14/24 4:37:26 PM ET
      $YTEN
    • Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets

      WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding ("MOU") and License Agreement with Nuseed Nutritional US Inc. (the seed technologies platform of Nufarm Limited (ASX:NUF)), granting Nufarm a commercial license to certain Omega-3 intellectual property assets, materials and know-how for producing oil in Camelina. Nufarm and Yield10 have additionally agreed to immediately negotiate exclusively with each other for the sale of Yield10's remaining assets to Nufarm. The asset sale will require an affirmative vote

      7/17/24 6:45:00 PM ET
      $YTEN

    $YTEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $YTEN
    SEC Filings

    See more

    $YTEN
    Financials

    Live finance-specific insights

    See more

    $YTEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $YTEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Yield10 Bioscience downgraded by Lake Street

      Lake Street downgraded Yield10 Bioscience from Buy to Hold

      2/8/24 7:25:58 AM ET
      $YTEN
    • Maxim Group reiterated coverage on Yield10 Bioscience with a new price target

      Maxim Group reiterated coverage of Yield10 Bioscience with a rating of Buy and set a new price target of $9.00 from $18.00 previously

      3/10/22 9:38:04 AM ET
      $YTEN
    • Maxim Group reiterated coverage on Yield10 Bioscience with a new price target

      Maxim Group reiterated coverage of Yield10 Bioscience with a rating of Buy and set a new price target of $24.00 from $12.00 previously

      2/9/21 4:14:42 PM ET
      $YTEN
    • Yield10 Bioscience Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Financial Statements and Exhibits

      8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)

      12/6/24 4:57:07 PM ET
      $YTEN
    • Yield10 Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)

      11/22/24 10:39:21 AM ET
      $YTEN
    • Yield10 Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)

      11/12/24 11:49:02 AM ET
      $YTEN
    • Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results

      -Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market-Advanced regulatory and seed scale-up program for omega-3 Camelina-E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada-Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023. "In 2023 we successfully executed our plan and achieved several

      4/1/24 4:01:07 PM ET
      $YTEN
    • Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024

      WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2023 financial results and provide a corporate update on Monday, April 1, 2024. Management will host a conference call on Monday, April 1, 2024.at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. Interested parties within the U.S. should call 1-877-709-8150 or +1-201-689-8354 (international) to listen to the call. Th

      3/28/24 4:01:20 PM ET
      $YTEN
    • Yield10 Bioscience to Announce Third Quarter 2023 Financial Results and Host a Conference Call on Tuesday, November 14, 2023

      WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its third quarter 2023 financial results and provide a corporate update on Tuesday, November 14, 2023. Management will host a conference call on Tuesday, November 14, 2023 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. Interested parties within the U.S. should call 1-800-715-9871 or +1-646-307-1963 (international) to listen to the call. The Conf

      11/8/23 8:31:35 AM ET
      $YTEN
    • SEC Form SC 13D/A filed by Yield10 Bioscience Inc. (Amendment)

      SC 13D/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)

      5/23/24 5:51:39 PM ET
      $YTEN
    • SEC Form SC 13D filed by Yield10 Bioscience Inc.

      SC 13D - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)

      10/11/23 4:05:24 PM ET
      $YTEN
    • SEC Form SC 13D/A filed by Yield10 Bioscience Inc. (Amendment)

      SC 13D/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)

      5/26/23 1:14:08 PM ET
      $YTEN
    • Yield10 Bioscience Appoints Willie Loh, Ph.D., Former Cargill Executive, to the Board of Directors

      WOBURN, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Willie Loh, Ph.D., was named to the Company's Board of Directors effective October 4, 2022. Dr. Loh previously served as a Special Commercial and Technical Advisor to the Company. Dr. Loh was formerly Vice President, Market Development of Cargill Inc.'s Global Edible Oils Solutions group in North America. Cargill is a global food and agriculture company. "We are delighted that Willie is expanding his role with Yield10 by serving on our Board of Directors," said Oliver Peoples, Ph.D., Chief Executive Officer of Yield1

      10/5/22 8:30:20 AM ET
      $YTEN